跳至主要内容
临床试验/EUCTR2013-003405-26-BE
EUCTR2013-003405-26-BE进行中(未招募)不适用

The effect of Lamotrigine on cognitive deficits associated with Neurofibromatosis type 1: a phase II randomized controlled multi-centre trial (NF1-EXCEL)

Erasmus MC0 个研究点目标入组 60 人开始时间: 2015年3月30日最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
进行中(未招募)
发起方
Erasmus MC
入组人数
60

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • NF1 patients with a genetically confirmed diagnosis
  • Age 12-17.5 years at inclusion
  • Oral and written informed consent by parents and assent from
  • participants
  • Are the trial subjects under 18? yes
  • Number of subjects for this age range: 60
  • F.1.2 Adults (18-64 years) no
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • Segmental NF1
  • Hearing problems or deafness
  • Use of the following medication: fenytoïn, carbamazepine,
  • fenobarbital, primidon, rifampicine, atazanavir/ritonavir,
  • lopinavir/ritonavir, oxcarbazepine, topiramate, oral contraceptive pill (with stopweek, containing both oestrogen and progestagen) and valproic acid during the last 3 months.
  • Previous use of lamotrigine
  • Previous allergic reactions to anti-epileptic drugs
  • Epilepsy or epilepsy in the past
  • Suicidal thoughts or behaviour
  • Renal insufficiency
  • Liver insufficiency
  • Pregnancy
  • Brain tumour or other brain pathology potentially influencing the outcome measures

研究者

发起方
Erasmus MC

相似试验